Download Free The Amgen Story Book in PDF and EPUB Free Download. You can read online The Amgen Story and write the review.

As the most successful biotech company in history and the eighth largest drug-producing company in the world, Amgen has improved the lives of millions of patients worldwide. In 2005, the company celebrates its twenty-fifth anniversary with the publication of "The Amgen Story. This stunning illustrated book contains hundreds of archival photos and compelling text from noted biotech writer David Ewing Duncan. It is testament and tribute to the staff, leaders, patients, and science that make each discovery possible.
Under Gordon Binder's leadership, Amgen became the world's largest and most successful biotech company in the world. This text describes what it really takes to manage risk, financing, creative employees, and intellectual property on the international stage.
* Instant WSJ bestseller * Translated into 18 languages * #1 Most Recommended Book of the year (Bloomberg annual survey of CEOs and entrepreneurs) * An Amazon, Bloomberg, Financial Times, Forbes, Inc., Newsweek, Strategy + Business, Tech Crunch, Washington Post Best Business Book of the year * Recommended by Bill Gates, Daniel Kahneman, Malcolm Gladwell, Dan Pink, Adam Grant, Susan Cain, Sid Mukherjee, Tim Ferriss Why do good teams kill great ideas? Loonshots reveals a surprising new way of thinking about the mysteries of group behavior that challenges everything we thought we knew about nurturing radical breakthroughs. Bahcall, a physicist and entrepreneur, shows why teams, companies, or any group with a mission will suddenly change from embracing new ideas to rejecting them, just as flowing water will suddenly change into brittle ice. Mountains of print have been written about culture. Loonshots identifies the small shifts in structure that control this transition, the same way that temperature controls the change from water to ice. Using examples that range from the spread of fires in forests to the hunt for terrorists online, and stories of thieves and geniuses and kings, Bahcall shows how a new kind of science can help us become the initiators, rather than the victims, of innovative surprise. Over the past decade, researchers have been applying the tools and techniques of this new science—the science of phase transitions—to understand how birds flock, fish swim, brains work, people vote, diseases erupt, and ecosystems collapse. Loonshots is the first to apply this science to the spread of breakthrough ideas. Bahcall distills these insights into practical lessons creatives, entrepreneurs, and visionaries can use to change our world. Along the way, readers will learn how chickens saved millions of lives, what James Bond and Lipitor have in common, what the movie Imitation Game got wrong about WWII, and what really killed Pan Am, Polaroid, and the Qing Dynasty. “If The Da Vinci Code and Freakonomics had a child together, it would be called Loonshots.” —Senator Bob Kerrey
Worth magazine founder Randy Jones shows how to pick the best stocks of the future by learning the lessons of the greatest stocks of all time. In a turbulent investing environment, luck must be the only way to score in the stock market, right? Not so, says Randy Jones. The people who bought McDonald’s in 1965 or Chrysler in 1980 weren’t just fortunate. Most of them knew how to read the signs of a good stock and jumped on the opportunity. Such stocks exist in every economic climate, and Jones shows readers exactly how to find them. In The Greatest Stock Picks of All Time, Jones describes twenty-five of the best stock picks ever and explains what made them great. He shows how the smartest investors find companies that are about to zoom, giving readers a framework for analyzing stocks today. For example, Jones explains why AT&T was a great stock pick in the 1920s, Polaroid in the 1940s, Xerox in the 1950s, Teledyne in the 1970s, and Intel in the 1990s. He then guides readers to discover stocks that represent the same kinds of pathbreaking products, innovative business models, great management teams, and other harbingers of success that will certainly be characteristic of the great stock picks of tomorrow. The Greatest Stock Picks of All Time has invaluable lessons for anyone in the market today. “Today a lot of people think they should murder their brokers, but my advice is don’t. You can stay out of jail and make a lot of money by learning from the greatest stocks of the last century and by heeding this advice for your future investments.” —Dominick Dunne
Biotechnology has not stood still since 1991 when the first edition of Biotechnology - The Science and the Business was published. It was the first book to treat the science and business of technology as an integrated subject and was well received by both students and business professionals. All chapters in this second edition have been updated and revised and some new chapters have been introduced, including one on the use of molecular genetic techniques in forensic science. Experts in the field discuss a range of biotechnologies, including pesticides, the flavor and fragrance industry, oil production, fermentation and protein engineering. On the business side, subjects include managing, financing, and regulation of biotechnology. Some knowledge of the science behind the technologies is assumed, as well as a layperson's view of buying and selling. As with the first edition, it is expected that this book will be of interest to biotechnology undergraduates, postgraduates and those working in the industry, along with students of business, economics, intellectual property law and communications.
“An incisive history of the venture-capital industry.” —New Yorker “An excellent and original economic history of venture capital.” —Tyler Cowen, Marginal Revolution “A detailed, fact-filled account of America’s most celebrated moneymen.” —New Republic “Extremely interesting, readable, and informative...Tom Nicholas tells you most everything you ever wanted to know about the history of venture capital, from the financing of the whaling industry to the present multibillion-dollar venture funds.” —Arthur Rock “In principle, venture capital is where the ordinarily conservative, cynical domain of big money touches dreamy, long-shot enterprise. In practice, it has become the distinguishing big-business engine of our time...[A] first-rate history.” —New Yorker VC tells the riveting story of how the venture capital industry arose from America’s longstanding identification with entrepreneurship and risk-taking. Whether the venture is a whaling voyage setting sail from New Bedford or the latest Silicon Valley startup, VC is a state of mind as much as a way of doing business, exemplified by an appetite for seeking extreme financial rewards, a tolerance for failure and experimentation, and a faith in the promise of innovation to generate new wealth. Tom Nicholas’s authoritative history takes us on a roller coaster of entrepreneurial successes and setbacks. It describes how iconic firms like Kleiner Perkins and Sequoia invested in Genentech and Apple even as it tells the larger story of VC’s birth and evolution, revealing along the way why venture capital is such a quintessentially American institution—one that has proven difficult to recreate elsewhere.
The first edition of the Encyclopedia of Cancer and Society was published in 2007 and received a 2008 Editors’ Choice Award from Booklist. It served as a general, non-technical resource focusing on cancer from the perspective of the social and behavioral sciences, exploring social and economic impacts, the "business" of cancer, advertising of drugs and treatment centers, how behavior change could offer great potential for cancer prevention, environmental risks, food additives and regulation, the relation between race and ethnicity and cancer risk, socioeconomic status, controversies—both scientific and political—in cancer treatment and research, country-by-country entries on cancer around the world, and more. Given various developments in the field including new drug treatments, political controversies over use of the vaccines Gardasil and Cervarix with young girls to prevent cervical cancer, and unexpected upticks in the prevalence of adult smoking within the U.S. following decades of decline, the SAGE Encyclopedia of Cancer and Society, Second Edition serves as an updated and more current encyclopedia that addresses concerns pertaining to this topic. Key Features: · Approximately half of the 700 first-edition articles revised and updated · 30+ new entries covering new developments since 2006 · Signed entries with cross-references · Further Readings accompanied by pedagogical elements · New Reader’s Guide · Updated Chronology, Resource Guide, Glossary, and through new Index The SAGE Encyclopedia of Cancer and Society, Second Edition serves as a reliable and precise source for students and researchers with an interest in social and behavioral sciences and seeks to better understand the continuously evolving subject matter of cancer and society.
Pharmaceuticals constitute a relatively small share of the total healthcare expenditure in most developed economies, and yet they play a critical role in the ongoing debate over how best to advance, improve, and afford healthcare. Despite this, and perhaps because of this, the industry has had, for many years, an outsized claim to fame and controversy, praise and criticisms, support and condemnation. Unfortunately, many participants in the debate do not fully understand the complexities of the industry and its role in the overall healthcare system. The analytical tools of economics provide a strong foundation for a better understanding of the dynamics of the pharmaceutical industry, its contribution to health and healthcare, its dual and often conflicting priorities of affordability and innovation, as well as the various private and public policy initiatives directed at the sector. This third edition of a uniquely comprehensive and balanced examination of the industry includes several new chapters on important topics such as the full-fledged generics sector, the arrival of biosimilars or generic biological drugs, the global consolidation of manufacturers, the evolving reimbursement landscape, and the emergence of the world's most populous nations, such as China, India, and Brazil, as both suppliers and consumers of pharmaceutical products. Other chapters have been fully rewritten or extensively updated, covering such important topics as the cost efficiency of research and development, pace of new innovations, economic evaluation and value-based pricing of drugs, and public and private interventions in the industry.